What one share of Dermata Therapeutics holds
We are a late-stage medical dermatology company focused on identifying, developing, and commercializing innovative pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications we believe represent significant market opportunities.
Dermata Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.35 |
|---|---|
| Cash and investments | $1.10 |
| Book value | $0.87 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$254.04 | — | — | — | −$249.44 |
| 2021 | — | −$364.86 | — | — | — | $182.03 |
| 2023 | — | −$399.88 | — | — | — | $242.56 |
| 2024 | — | −$80.32 | — | — | — | $6.20 |
| 2025 | — | −$8.16 | — | — | — | $2.34 |
Common questions about Dermata Therapeutics
How much does one share of Dermata Therapeutics earn?
Over the last 12 months, Dermata Therapeutics lost $3.35 for each share.
Does Dermata Therapeutics pay a dividend?
Dermata Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Dermata Therapeutics’s book value per share?
Dermata Therapeutics’s book value is $0.87 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Dermata Therapeutics have?
Each share of Dermata Therapeutics has $1.10 of cash and investments, as of June 30, 2026.
Has Dermata Therapeutics bought back shares?
Dermata Therapeutics’s share count rose about 7170% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.